TrialInvestigational new drugs2012

A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.

Robert M Rifkin et al.PubMed ↗Publisher ↗

No numbers read from the abstract.